IL5 and vasculitis: Furthermore, in recent years, several cases have been reported where patients undergoing anti-IL-5 therapy targeting T2-eosinophilic inflammation experienced a relapse of vasculitis in EGPA, marked by an increase in ANCA levels, despite having normal eosinophil counts (48, 49).